MENEST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENEST (MENEST).
Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.
| Metabolism | Conjugated estrogens are metabolized primarily in the liver via hydroxylation and conjugation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2D6) and undergo enterohepatic recirculation. |
| Excretion | Estrogens are excreted primarily in urine (about 90-95%) as glucuronide and sulfate conjugates. The remaining 5-10% is excreted in feces via bile. Less than 5% is excreted unchanged. |
| Half-life | The terminal elimination half-life of conjugated estrogens is approximately 10-24 hours. The half-life of estrone, the primary metabolite, is about 12-18 hours. This supports once-daily dosing. |
| Protein binding | Estrogens are approximately 50-80% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. Estrone is about 16% bound to SHBG and 80% to albumin; estradiol has higher SHBG affinity. |
| Volume of Distribution | The apparent volume of distribution for conjugated estrogens is not well-defined due to tissue binding. For estradiol, Vd is approximately 1.2 L/kg, indicating extensive distribution into tissues and fat. |
| Bioavailability | Oral bioavailability of conjugated estrogens is approximately 40-50% due to first-pass hepatic metabolism. The tablet formulation is designed to deliver a consistent dose; enteric-coated tablets may have slightly different bioavailability. |
| Onset of Action | Oral administration: Clinical effects (e.g., relief of vasomotor symptoms) may be observed within 2-4 weeks of continuous therapy. Maximal estrogenic effects on vaginal epithelium occur after several weeks. |
| Duration of Action | The duration of action following a single oral dose is approximately 24 hours, consistent with once-daily dosing. Withdrawal bleeding may occur 2-3 days after discontinuation in cyclic regimens. |
0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.
| Dosage form | TABLET |
| Renal impairment | No specific dosing adjustment recommended; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C); for mild to moderate impairment (Child-Pugh A or B), use lowest effective dose and monitor liver function. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Initiate at lowest effective dose (0.3 mg daily) due to increased sensitivity and risk of adverse effects; monitor closely for thromboembolic events and malignancy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MENEST (MENEST).
| Breastfeeding | Estrogens are excreted in human milk in small amounts. M/P ratio not established. Use during breastfeeding is not recommended as it may reduce milk production and affect infant development. |
| Teratogenic Risk | First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associated with fetal genital tract abnormalities, increased risk of spontaneous abortion, and preterm delivery. Estrogens are contraindicated in pregnancy. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Unopposed estrogen use increases the risk of endometrial hyperplasia and carcinoma. Estrogens should not be used in women with undiagnosed abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Estrogens increase the risk of venous thromboembolism, stroke, and myocardial infarction.
| Serious Effects |
["Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Active liver disease or impaired liver function","Known or suspected breast cancer (except in selected metastatic cases)","Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer)","Active or history of venous thromboembolism","Active or history of arterial thromboembolism (e.g., stroke, MI)","Hypersensitivity to estrogens or any ingredient in Menest"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction","Malignant neoplasms: increased risk of endometrial cancer and possibly breast cancer","Gallbladder disease","Hypertriglyceridemia","Fluid retention","Hypocalcemia","Hereditary angioedema","Exacerbation of endometriosis","Visual abnormalities","Dementia risk (when initiated in women >65 years)","Jaundice and liver function abnormalities"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of thrombosis, hypertension, and hepatic dysfunction. Fetal monitoring includes serial ultrasound to assess growth and anatomy, especially for urogenital anomalies. |
| Fertility Effects | Estrogens can suppress ovulation and reduce fertility when used as contraception. In therapeutic doses, they may inhibit gonadotropin secretion, potentially delaying conception. Reversible upon discontinuation. |